Amelioration of diabetes by imatinib mesylate (Gleevec®): role of ‐cell NF‐KB activation and anti‐apoptotic preconditioning

No abstract is available for this paper.

• Publication year

  2007

• Venue

  The FASEB Journal

• Publication date

  2007-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1096/fj.06-6910com
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Imatinib mesylate (Gleevec) protects against streptozotocin‐induced diabetes and islet cell death in vitro

  2006cited by this paper
• Imatinib and hyperlipidemia.

  2005cited by this paper
• Imatinib and regression of type 2 diabetes.

  2005cited by this paper
• siRNA Produced by Recombinant Dicer Mediates Efficient Gene Silencing in Islet Cells

  2005influential reference
• An immune origin of type 2 diabetes?

  2005cited by this paper
• c-Abl Tyrosine Kinase Regulates Caspase-9 Autocleavage in the Apoptotic Response to DNA Damage*

  2005cited by this paper
• Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment.

  2004cited by this paper
• Ischaemic preconditioning: from molecular characterisation to clinical application--part I.

  2004cited by this paper
• A novel structural class of potent inhibitors of NF-kappa B activation: structure-activity relationships and biological effects of 6-aminoquinazoline derivatives.

  2003cited by this paper
• Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571.

  2003cited by this paper
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• Protection of rat pancreatic islets by potassium channel openers against alloxan, sodium nitroprusside and interleukin-1β mediated suppression—possible involvement of the mitochondrial membrane potential

  2003cited by this paper
• Preconditioning the myocardium: from cellular physiology to clinical cardiology.

  2003cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine.

  2002cited by this paper
• Cytokine-induced apoptosis and necrosis are preceded by disruption of the mitochondrial membrane potential (Δψm) in pancreatic RINm5F cells: prevention by Bcl-2

  2002cited by this paper
• Inactivation of NF-κB-Dependent Cell Survival, a Novel Mechanism for the Proapoptotic Function of c-Abl

  2002cited by this paper
• β-Cell death during progression to diabetes

  2001cited by this paper
• Targeting of the c-Abl Tyrosine Kinase to Mitochondria in Endoplasmic Reticulum Stress-Induced Apoptosis

  2001cited by this paper
• Nitric oxide-induced apoptosis in pancreatic β cells is mediated by the endoplasmic reticulum stress pathway

  2001cited by this paper
• Choosing between growth arrest and apoptosis through the retinoblastoma tumour suppressor protein, Abl and p73.

  2001cited by this paper
• ARG tyrosine kinase activity is inhibited by STI571.

  2001cited by this paper
• Evidence for mitochondrial K ATP channels as effectors of human myocardial preconditioning.

  2000cited by this paper
• Activation of MEK Kinase 1 by the c-Abl Protein Tyrosine Kinase in Response to DNA Damage

  2000cited by this paper
• Activation of the Cytoplasmic c-Abl Tyrosine Kinase by Reactive Oxygen Species*

  2000cited by this paper
• Printed in U.S.A. Copyright © 2000 by The Endocrine Society Cytokines Induce Both Necrosis and Apoptosis via a Common Bcl-2-Inhibitable Pathway in Rat Insulin-Producing Cells*

  1999cited by this paper
• The NOD mouse model of type 1 diabetes: As good as it gets?

  1999cited by this paper
• Cycling, stressed-out and nervous: cellular functions of c-Abl.

  1999cited by this paper
• Signal Transduction in Ischemic Preconditioning:

  1999influential reference
• Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

  1996cited by this paper
• Interleukin-1β Induced Activation of NF-κB in Insulin-Producing RINm5F Cells Is Prevented by the Protease Inhibitor Nα-p-Tosyl-L-Lysine Chloromethylketone

  1994cited by this paper
• Interleukin-1 beta-induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the Krebs cycle enzyme aconitase.

  1991cited by this paper
• Studies on the diabetogenic action of streptozotocin (NSC-37917).

  1963cited by this paper
• Studies on the diabetogenic action of streptozotocin

  1963cited by this paper
• Printed in U.S.A. Copyright © 1999 by The Endocrine Society Sodium Palmitate Induces Partial Mitochondrial Uncoupling and Reactive Oxygen Species in Rat Pancreatic Islets in Vitro*

  year unknowncited by this paper
• Interleukin-1 (cid:98) -induced Ceramide and Diacylglycerol Generation May Lead to Activation of the c-Jun NH 2 -terminal Kinase and the Transcription Factor ATF2 in the Insulin-producing Cell Line RINm5F*

  year unknowncited by this paper

• Potential impact of tyrosine kinase inhibitors on glycemic control and diabetes mellitus progression: a clinical appraisal

  2025cites this paper
• Disease-modifying pharmacological treatments of type 1 diabetes: Molecular mechanisms, target checkpoints, and possible combinatorial treatments

  2025cites this paper
• Targeting Protein Kinases to Protect Beta-Cell Function and Survival in Diabetes

  2024cites this paper
• Cancer knocks you out by fasting: Cachexia as a consequence of metabolic alterations in cancer

  2024cites this paper
• Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid Leukemia

  2024cites this paper
• The Role of Imatinib in Pediatric Type 1 Diabetes.

  2024cites this paper
• GDF15 Protects Insulin-Producing Beta Cells against Pro-Inflammatory Cytokines and Metabolic Stress via Increased Deamination of Intracellular Adenosine

  2024cites this paper
• Pharmacological inhibitors of β-cell dysfunction and death as therapeutics for diabetes

  2023cites this paper
• Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

  2023cites this paper
• Preservation of β-Cells as a Therapeutic Strategy for Diabetes

  2023cites this paper
• Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications

  2023cites this paper
• Imatinib prevents dexamethasone‐induced pancreatic β‐cell apoptosis via decreased TRAIL and DR5

  2023cites this paper
• Future treatment of Diabetes – Tyrosine Kinase inhibitors

  2022cites this paper
• Exercise as a non-pharmacological intervention to protect pancreatic beta cells in individuals with type 1 and type 2 diabetes

  2022cites this paper
• Sorafenib decreases glycemia by impairing hepatic glucose metabolism

  2022cites this paper
• Are off-target effects of imatinib the key to improving beta-cell function in diabetes?

  2022cites this paper
• Tyrosine Kinase Targeting: A Potential Therapeutic Strategy for Diabetes

  2022influential citation
• Neue Ansätze zur Regeneration der insulinproduzierenden β-Zelle

  2022cites this paper
• Preventing type 1 diabetes development and preserving beta-cell function

  2022cites this paper
• From Pancreatic b-Cell Gene Networks to Novel Therapies for Type 1 Diabetes

  2021cites this paper
• From Pancreatic β-Cell Gene Networks to Novel Therapies for Type 1 Diabetes

  2021cites this paper
• Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

  2021cites this paper
• Pathologic HIF1α signaling drives adipose progenitor dysfunction in obesity.

  2021cites this paper
• Late Treatment Effects and Cancer Survivor Care in the Young: From Childhood to Early Adulthood

  2021influential citation
• An accomplice more than a mere victim: The impact of β-cell ER stress on type 1 diabetes pathogenesis

  2021cites this paper
• Imatinib protects against human beta-cell death via inhibition of mitochondrial respiration and activation of AMPK.

  2021cites this paper
• Effect of Sorafenib on Sex Hormone Levels in Male Swiss Albino Mice

  2021cites this paper
• Pharmacological Targeting of Endoplasmic Reticulum Stress in Pancreatic Beta Cells.

  2020cites this paper
• Modulatory role of imatinib mesylate on pancreatic β-cells' secretory functions in an STZ rat model of diabetes mellitus.

  2020cites this paper
• Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure

  2020cites this paper
• B Cell Metabolism: An Understudied Opportunity to Improve Immune Therapy in Autoimmune Type 1 Diabetes

  2020cites this paper
• Side Effects and Sequelae of Treatment for Chronic Myeloid Leukemia in Childhood and Adolescence

  2020cites this paper
• New Frontiers in the Treatment of Type 1 Diabetes.

  2019cites this paper
• 1 B lymphocytes protect islet beta cells in diabetes prone NOD mice treated with imatinib

  2019cites this paper
• Discovery of 5-(3,4-Difluorophenyl)-3-(pyrazol-4-yl)-7-azaindole (GNF3809) for β-Cell Survival in Type 1 Diabetes

  2019cites this paper
• B lymphocytes protect islet β cells in diabetes prone NOD mice treated with imatinib.

  2019cites this paper
• KIT as a therapeutic target for non‐oncological diseases

  2019cites this paper
• Glucocorticoids and checkpoint tyrosine kinase inhibitors stimulate rat pancreatic beta cell proliferation differentially

  2019cites this paper
• Imatinib mesylate improves insulin sensitivity and glucose disposal rates in high-fat diet fed rats

  2019cites this paper
• Imatinib reduces non-alcoholic fatty liver disease in obese mice by targeting inflammatory and lipogenic pathways in macrophages and liver

  2018cites this paper
• Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor

  2018cites this paper
• Life threatening hypoglycaemia in a child with infantile myofibromatosis

  2018cites this paper
• Epidemiologická studie nových perorálních antikoagulancií

  2018cites this paper
• Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors.

  2018cites this paper
• Repression of the Notch pathway prevents liver damage in streptozotocin-induced diabetic mice.

  2017cites this paper
• Novel members of quinoline compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue

  2017cites this paper
• Sunitinib specifically augments glucose-induced insulin secretion.

  2017cites this paper
• Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes.

  2017cites this paper
• From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview

  2017cites this paper
• Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes.

  2017cites this paper
• Combination Immunotherapy for Type 1 Diabetes

  2017cites this paper
• Chapter 5 – Imatinib

  2017cites this paper
• Pharmacological Macrophage Attenuation by Imatinib Reverts Hepatic Steatosis and Inflammation in Obese Mice

  2017cites this paper
• PPARγ Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue

  2016cites this paper
• The role of the Src Homology-2 domain containing protein B (SHB) in β cells.

  2016influential citation
• Imatinib prevents beta cell death in vitro but does not improve islet transplantation outcome

  2016cites this paper
• Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia

  2016cites this paper
• Evaluation of the potential synergism of imatinib‐related poly kinase inhibitors using growth factor stimulated proteoglycan synthesis as a model response

  2016influential citation
• Herbal Anti-Hyperglycemic Compound Improves Glycemic Control and Insulin Sensitivity in Diabetic Rats

  2016cites this paper
• Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes

  2016cites this paper
• Dasatinib improves insulin sensitivity and affects lipid metabolism in a patient with chronic myeloid leukaemia

  2016cites this paper
• Polyphenols isolated from Broussonetia kazinoki prevent cytokine-induced β-cell damage and the development of type 1 diabetes

  2015cites this paper
• Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells.

  2015cites this paper
• Oxidative Stress Type Influences the Properties of Antioxidants Containing Polyphenols in RINm5F Beta Cells

  2015cites this paper
• Non-receptor tyrosine kinase inhibitors enhances β-cell survival by suppressing the PKCδ signal transduction pathway in streptozotocin-induced β-cell apoptosis.

  2015cites this paper
• Role of the AMP kinase in cytokine-induced human EndoC-βH1 cell death.

  2015cites this paper
• Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome.

  2015cites this paper
• Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury.

  2015cites this paper
• Sunitinib-induced severe hypoglycemia in a diabetic patient

  2014cites this paper
• Inhibition of c-Kit Is Not Required for Reversal of Hyperglycemia by Imatinib in NOD Mice

  2014cites this paper
• Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment

  2014cites this paper
• C-Abl Inhibitor Imatinib Enhances Insulin Production by β Cells: C-Abl Negatively Regulates Insulin Production via Interfering with the Expression of NKx2.2 and GLUT-2

  2014cites this paper
• The pharmacokinetics and hypoglycaemic effect of sunitinib in the diabetic rabbits

  2014cites this paper
• How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review.

  2014cites this paper
• Hypoglycemic Coma in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib

  2014cites this paper
• The H1-Receptor Antagonist Cetirizine Protects Partially Against Cytokine- and Hydrogen Peroxide–Induced &bgr;-TC6 Cell Death In Vitro

  2014cites this paper
• Enhanced vascular endothelial growth factor signaling in islets contributes to β cell injury and consequential diabetes in spontaneously diabetic Torii rats.

  2014cites this paper
• AMP-dependent Kinase Inhibits Oxidative Stress-induced Caveolin-1 Phosphorylation and Endocytosis by Suppressing the Dissociation between c-Abl and Prdx1 Proteins in Endothelial Cells*

  2013cites this paper
• Inhibition of VEGFR-2 Reverses Type 1 Diabetes in NOD Mice by Abrogating Insulitis and Restoring Islet Function

  2013cites this paper
• Small‐molecule inhibition of inflammatory β‐cell death

  2013cites this paper
• Composés et compositions pour l'inhibition de l'activité abl1, abl2 et bcr-abl1

  2013cites this paper
• Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes

  2013cites this paper
• Transformation of Nonfunctioning Pancreatic Neuroendocrine Carcinoma Cells into Insulin Producing Cells after Treatment with Sunitinib

  2013cites this paper
• Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5′-phosphatase interaction with c-Abl

  2013cites this paper
• Inhibition of Nuclear Factor-κB Activation in Pancreatic β-Cells Has a Protective Effect on Allogeneic Pancreatic Islet Graft Survival

  2013cites this paper
• Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors

  2013cites this paper
• Tyrphostin AG490 Agent Modestly but Significantly Prevents Onset of Type 1 in NOD Mouse; Implication of Immunologic and Metabolic Effects of a Jak-Stat Pathway Inhibitor

  2012cites this paper
• Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus.

  2012cites this paper
• Selective Targeting of c-Abl via a Cryptic Mitochondrial Targeting Signal Activated by Cellular Redox Status in Leukemic and Breast Cancer Cells

  2012cites this paper
• Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma.

  2012cites this paper
• Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes

  2012cites this paper
• Does the small tyrosine kinase inhibitor imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis?

  2012cites this paper
• The Tyrphostin Agent AG490 Prevents and Reverses Type 1 Diabetes in NOD Mice

  2012cites this paper
• Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion.

  2012cites this paper
• Influence of Tyrphostin AG490 on the expression of diabetes-associated markers in human adipocytes

  2012cites this paper
• Uncoupling protein-2 increases nitric oxide production and TNFAIP3 pathway activation in pancreatic islets

  2011cites this paper
• Nilotinib counteracts thioacetamide‐induced hepatic oxidative stress and attenuates liver fibrosis progression

  2011cites this paper
• Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: a case report.

  2011cites this paper
• Effects of Imatinib Mesylate (Gleevec) on Human Islet NF-kappaB Activation and Chemokine Production In Vitro

  2011cites this paper
• Endocrine side effects of broad-acting kinase inhibitors.

  2010cites this paper